Novocure Limited
A maker of cancer treatments that harness electricity rather than drugs, Novocure produces the Optune device, a wearable system that delivers low-intensity electric fields (called Tumor Treating Fields) to slow tumor growth in adults with glioblastoma, an aggressive brain cancer. It was founded in 2000 by Yoram Palti, a biophysicist who first tested his theory in a lab he set up in the basement of his home in Israel.
Granted 603.5K · Sold 237.0K
Granted 369.7K · Bought 81.5K · Sold 31.4K
Granted 615.7K · Bought 5.0K · Sold 212.5K
Granted 268.8K · Sold 42.2K
Granted 265.6K · Sold 30.2K
Granted 225.6K
Granted 52.2K · Sold 4.9K
Granted 206.8K · Sold 4.7K
Granted 400.3K · Sold 75.1K
Granted 110.1K · Bought 20.0K · Sold 6.4K
Granted 88.6K · Sold 43.2K
Granted 106.1K · Sold 3.1K
Granted 33.2K · Sold 4.9K
Granted 130.2K · Sold 55.8K
Granted 51.1K
Granted 48.9K · Sold 8.7K
Sold 5.4K
Granted 29.3K · Sold 3.9K
Granted 15.7K · Sold 999
Granted 17.7K · Sold 12.9K
Granted 30.7K · Sold 4.9K
Granted 26.9K · Sold 4.4K
Granted 26.9K · Sold 3.9K
Granted 26.9K · Sold 3.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leonard Frank XChief Executive Officer · 78 transactions | +415.4% | 459.5K | 603.5K | — | 237.0K |
| Cordova AshleyFormer Chief Executive Officer · 43 transactions | +818.8% | 422.6K | 369.7K | 81.5K | 31.4K |
| Danziger AsafDirector · 24 transactions | +4916.6% | 416.5K | 615.7K | 5.0K | 212.5K |
| Groenhuysen Wilhelmus CMChief Operating Officer · 26 transactions | — | 376.7Kas of Jun 2024 | 268.8K | — | 42.2K |
| Weinberg UriChf Medical and Innovation Ofr · 22 transactions | +740.7% | 267.2K | 265.6K | — | 30.2K |
| Ben Arye BarakGeneral Counsel · 13 transactions | — | 242.5K | 225.6K | — | — |
| Vernon W AnthonyDirector · 8 transactions | +29.2% | 209.3K | 52.2K | — | 4.9K |
| Puri Michal NathChief Human Resources Officer · 13 transactions | — | 201.3K | 206.8K | — | 4.7K |
| Doyle William FExecutive Chairman, Director · 6 transactions | -63.9% | 200.0K | 400.3K | — | 75.1K |
| Brackmann ChristophChief Financial Officer · 7 transactions | — | 182.8K | 110.1K | 20.0K | 6.4K |
| Shah PriteshChief Growth Officer · 25 transactions | +67.9% | 124.5Kas of Nov 2023 | 88.6K | — | 43.2K |
| Leupin NicolasFormer Chief Medical Officer · 6 transactions | — | 103.0K | 106.1K | — | 3.1K |
| Leung GabrielDirector · 8 transactions | +38.8% | 101.1K | 33.2K | — | 4.9K |
| Paravasthu MukundChief Operating Officer · 18 transactions | — | 72.8K | 130.2K | — | 55.8K |
| Giladi MosheChief Science Officer · 1 transaction | — | 69.8Kas of Feb 2024 | 51.1K | — | — |
| Burke William PatrickChief Human Resources Officer · 19 transactions | — | 66.4Kas of Jun 2023 | 48.9K | — | 8.7K |
| Longsworth Todd ChristopherGeneral Counsel · 3 transactions | -8% | 62.5Kas of Mar 2022 | — | — | 5.4K |
| Hung DavidDirector · 6 transactions | +377.7% | 32.1K | 29.3K | — | 3.9K |
| Madden Martin J.Director · 3 transactions | +93.9% | 30.3K | 15.7K | — | 999 |
| Benaim ElyChief Medical Officer · 11 transactions | +2.2% | 28.8Kas of Jan 2023 | 17.7K | — | 12.9K |
| Scannell Timothy JDirector · 7 transactions | +34430.7% | 25.9K | 30.7K | — | 4.9K |
| Hilleman Jeryl LDirector · 6 transactions | +765.2% | 25.5K | 26.9K | — | 4.4K |
| Ocean Allyson JDirector · 5 transactions | — | 22.9K | 26.9K | — | 3.9K |
| Stafford KristinDirector · 5 transactions | — | 22.9K | 26.9K | — | 3.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -694.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.